Caisse DE Depot ET Placement DU Quebec Raises Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Caisse DE Depot ET Placement DU Quebec has increased its stake in Johnson & Johnson by 22.6%, now owning approximately 3.6 million shares valued at around $597 million.
• Several hedge funds have also recently increased their holdings in Johnson & Johnson, indicating growing institutional interest as 69.55% of the stock is currently owned by institutional investors.
• Analysts have a consensus rating of "Moderate Buy" for Johnson & Johnson, with a target price of $176.29 following various upgrades and downgrades from different firms.

Caisse DE Depot ET Placement DU Quebec increased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 22.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,601,147 shares of the company's stock after purchasing an additional 664,556 shares during the period. Johnson & Johnson makes up approximately 1.3% of Caisse DE Depot ET Placement DU Quebec's portfolio, making the stock its 15th biggest holding. Caisse DE Depot ET Placement DU Quebec owned approximately 0.15% of Johnson & Johnson worth $597,214,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Talisman Wealth Advisors LLC grew its stake in Johnson & Johnson by 2.8% in the 1st quarter. Talisman Wealth Advisors LLC now owns 13,170 shares of the company's stock worth $2,184,000 after buying an additional 355 shares in the last quarter. Evergreen Wealth Solutions LLC lifted its holdings in shares of Johnson & Johnson by 2.7% during the 1st quarter. Evergreen Wealth Solutions LLC now owns 3,959 shares of the company's stock worth $657,000 after acquiring an additional 104 shares during the last quarter. Apexium Financial LP lifted its holdings in shares of Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company's stock worth $3,978,000 after acquiring an additional 2,310 shares during the last quarter. Independent Franchise Partners LLP grew its position in Johnson & Johnson by 2.1% in the first quarter. Independent Franchise Partners LLP now owns 5,302,536 shares of the company's stock worth $879,373,000 after acquiring an additional 108,065 shares in the last quarter. Finally, ICONIQ Capital LLC increased its stake in Johnson & Johnson by 114.0% in the first quarter. ICONIQ Capital LLC now owns 10,091 shares of the company's stock valued at $1,673,000 after acquiring an additional 5,375 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Morgan Stanley boosted their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Guggenheim reiterated a "neutral" rating and set a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $176.29.

Johnson & Johnson Price Performance

JNJ opened at $179.0980 on Monday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock's 50 day simple moving average is $163.48 and its 200 day simple moving average is $159.30. The firm has a market cap of $431.33 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 2.28 and a beta of 0.41. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the company posted $2.82 earnings per share. The business's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.